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Abstract
BACKGROUND: Moyamoya disease (MMD) is a peculiar disease, characterized by progressive steno-occlusion 
of the distal ends of bilateral internal carotid arteries and their proximal branches. Numerous studies of MMD 
investigated as a singular pathway, thus overlooked the complexity of MMD pathobiology. 
AIM: In this study, we sought to investigate the gene expression in the involved arteries to reveal the novel 
mechanism of MMD.
MATERIALS AND METHODS: Eight middle cerebral artery (MCA) specimens were obtained from six patients 
underwent surgical procedure superficial temporal artery to MCA (STA-MCA bypass) for MMD and two control 
patients. We performed RNA extraction and microarray analysis with Agilent Whole Human Genome DNA microarray 
4x44K ver.2.0 (Agilent Tech., Inc., Wilmington, DE, USA).
RESULTS: From 42,405 gene probes assayed, 921 gene probes were differentially regulated in MCA of patients 
with MMD. Subsequent pathway analysis with PANTHER database revealed that angiogenesis, inflammation, 
integrin, platelet-derived growth factor (PDGF), and WNT pathways were distinctly regulated in MMD. Among genes 
in aforementioned pathways, SOS1 and AKT2 were the mostly distinctly regulated genes and closely associated 
with RAS pathway.
CONCLUSION: The gene expression in MCA of patients with MMD was distinctly regulated in comparison with 
control MCA; presumably be useful for elucidating MMD pathobiology.
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Introduction
Moyamoya disease (MMD) is a peculiar disease, 
characterized by progressive steno-occlusion of the distal 
ends of bilateral internal carotid arteries (ICAs) and their 
proal vascular network at the base of the brain (moyamoya 
vessels) is formed as a result of progressive ischemic 
changes in the brain [1], [2], [3]. The high incidence of 
MMD in Japanese population and high proportion of 
familial cases suggest the involvement of a genetic factor, 
particularly polymorphism in RNF213 gene [4], [5], [6].
Pathological evaluations on autopsy subjects 
have demonstrated that the main vascular lesion in MMD 
is steno-occlusion of distal ICA caused by a fibrocellular 
intimal thickening with a multilayered elastic lamina and 
some lipid deposits [3], [7], [8], [9]. Despite there is an intimal 
proliferation, the media layer thickness is thinner [2], [10], and 
the smooth muscle cells undergo apoptosis [11].
Previous studies have revealed an abnormal 
expression of various angiogenesis-related genes 
and their products in MMD [2], [12], [13], [14], [15]. Of 
note, those studies mainly focused on a single or few 
interrelated genes or products at a time. Several studies 
reported that mutant RNF213 mice could not recapitulate 
MMD pathology in vivo [16], [17]. In addition, the 
phenotype also could manifest as secondary to pre-
existing diseases [18], [19], [20], [21].
Hence, pathobiology of MMD might involve 
multiple pathways rather than single pathway. In this 
study, we collected tiny pieces of middle cerebral artery 
(MCA) walls from patients with MMD and analyzed 
global gene expression using RNA microarray to explore 
the novel mechanism of remodeling of the arterial walls 
in the MMD patients.
Materials and Methods
Patients’ population
This study was performed under our 
institution guidelines provided by the ethics committee 
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in our center as being described in our previous 
reports [3], [10], [11], [22]. Six patients underwent 
superficial temporal artery to MCA (STA-MCA) bypass 
procedures for the treatment of MMD at our center. In 
addition, we included two patients with large cerebral 
artery aneurysms that underwent bypass procedure as 
control. Clinical data of the patients were summarized 
in Table 1.
Sample collection
During STA-MCA bypass surgery, a 10 or 
11–0 nylon monofilament was passed around the 
wall of the recipient artery. Then, vessel was pulled 
up by lifting the monofilament with forceps, and 
the operators (YT, SM) performed arteriotomy with 
micro-scissors (Figure 1). Then, collected tissues 
were rinsed with cold phosphate-buffered saline 
and immediately placed into RNAlater (Ambion, 
Austin, TX, USA) and stored at −80°C until RNA 
extraction. The control specimens were obtained in 
a similar manner as being described in our previous 
reports [3], [10], [11], [22].
Figure 1: Intraoperative view of the specimen collection procedure. 
The vessel was pulled up by lifting the monofilament with forceps, 
and the arteriotomy was performed with micro-scissors. White arrow 
indicates tiny piece of artery for microarray analysis
RNA preparation
Total RNA was isolated separately from 6 MMD 
and 2 control MCA specimens using RNAqueous-Micro 
Kit (Ambion, Austin, TX, USA). The concentration and 
quality of RNA were determined using Agilent 2100 
Bioanalyzer (Agilent Technologies, Inc., Wilmington, 
DE, USA). The extracted RNA was used for further 
procedures.
Microarray analysis
Microarray analysis was conducted by 
DNA Chip Research Inc. (Yokohama, Japan). RNA 
amplification was performed with Ovation® Pico-WTA 
(NuGEN Technologies, Inc., San Carlos, CA, USA). In 
brief, 500 pg of total RNA was reversely transcribed with 
random and oligo-dT primer. Then, the resultant first-
strand complementary DNA (cDNA) was used to make 
the second strand. The purified cDNA was processed 
with SPIA® primer (NuGEN Technologies, San Carlos, 
CA, USA) and DNA polymerase to make a sufficient 
dose of cDNA. Purified cDNA was labeled with cyanin3, 
then hybridized to the Agilent Whole Human Genome 
DNA microarray 4x44K ver. 2.0 (Agilent Technologies, 
Inc., Wilmington, DE, USA). After washing, the 
microarray chip was scanned with DNA MicroArray 
Scanner (Agilent Tech.).
Data analysis
The data were digitalized with Feature 
Extraction ver. 9.5.3 (Agilent Technologies, Inc., 
Wilmington, DE, USA) as the manufacture’s protocol. 
The digitalized data were imported into GeneSpring 
GX 11 (Agilent Technologies, Inc., Wilmington, DE, 
USA) and processed with the 75th percentile shift and 
followed by quantile normalization. Normalization also 
performed among the genes with adjusted baseline to 
median of all sample. Each spot data were flagged in 
accordance with the feature and cut off if the feature is 
saturated, not uniform, population outlier, not positive, 
not significant, or not above background.
Analysis was performed using the base-2 
logarithm transform of the normalized signal data 
with Office Excel 2010 (Microsoft, WA, USA). Welch’s 
t-test was used to identify the differentially expressed 
genes in MMD compare to control, and p < 0.05 was 
considered statistically significant. The genes were 
ranked according to their fold change and selected by 
criteria of fold change >2.0 for further pathway analysis 
with the online database PANTHER [23].
Results
As difficulty is expected, before the RNA 
preparation of these rare human surgical samples, 
we optimized our protocol of RNA extraction through 
Table 1: Clinical features of 2 Control and 6 patients with MMD
Age Sex Diagnosis Onset symptom Surgery Concomitant vascular risk factors
60 F Cerebral aneurysm Incident STA-MCA bypass & clipping HTN (-), Dyslipidemia (-), DM (-), Smoking (-)
52 F Cerebral aneurysm SAH ECA-MCA bypass & trapping HTN (-), Dyslipidemia (-), DM (-), Smoking (-)
50 F MMD Adult/Ischemia STA-MCA bypass HTN (-), Dyslipidemia (-), DM (-), Smoking (-)
43 M MMD Adult/Ischemia STA-MCA bypass HTN (-), Dyslipidemia (-), DM (-), Smoking (-)
31 F MMD (Unilateral) Adult/Ischemia STA-MCA bypass HTN (-), Dyslipidemia (-), DM (-), Smoking (-)
42 F MMD (Unilateral) Adult/Ischemia STA-MCA bypass HTN (-), Dyslipidemia (-), DM (-), Smoking (-)
44 F MMD Adult/Ischemia STA-MCA bypass HTN (-), Dyslipidemia (-), DM (-), Smoking (-)
41 F MMD (Unilateral) Adult/Ischemia STA-MCA bypass HTN (-), Dyslipidemia (-), DM (-), Smoking (-)
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animal experimentation in mice. We found that the 
manufacture’s protocol was effective for RNA extraction 
from a small piece of mice blood vessels. However, the 
quality of extracted RNA from surgical specimens was 
not entirely satisfactory, RNA integrity number below 
ideal value for microarray analysis (r < 7). We decided 
to accomplish the microarray as the screening work 
with the current available method.
Figure 2: Normalized gene expression of distal MCA from MMD 
patients with > 2.0 fold change. A total of 921 genes were distinctly 
regulated, 499 genes were up-regulated, and 422 genes were 
down-regulated
In this study, 42,405 gene probes remained 
after filtering for flags. Then, we selected the gene 
expression based on fold change >2.0 and p < 0.05; 
as a result, 921 genes were found distinctly regulated 
between MCA of MMD and control. MCA of MMD was 
found to up-regulate 499 genes expression and down-
regulate 422 genes expression compare to control 
(Figure 2). 
Figure 3: Normalized gene expression of distal MCA from MMD 
patients in angiogenesis pathway with > 2.0 fold change. A total of 12 
genes were distinctly regulated, 10 genes were up-regulated, and 2 
genes were down-regulated
Among them, for example, SOS1 (Fold 
change: 6.01 detected with each probe), AKT2 (5.71), 
OCLN (5.40), CD34 (4.38), HEY1 (3.68), ITGB2 
(3.63), CLDN5 (3.40), SELP (2.86), NES (2.39), 
BAMBI (2.38), IL1B (2.31), STAT1 (2.27), APOE 
(1.95), RB1 (1.94), ELN (1.93), NOTCH4 (1.86), 
ENG (1.48) and TLR4 (1.47) are up-regulated, and 
ACTN2 (2.72), IGFBP4 (2.61), SOX4 (2.27), DES 
(1.92), JunD (1.89), ETV6 (1.80), AKT1 (1.27), and 
XBP1 (1.09) are down-regulated. In this study, major 
angiogenic factors, such as vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor 
(FGF), or RNF213, did not show a significant change 
in this study. On the other hand, Endoglin, previously 
reported as highly expressed in the endothelium 
of cerebral arterial wall of MMD patients, also 
up-regulated in this study.
Figure 4: Normalized gene expression of distal MCA from MMD 
patients in inflammatory pathway with > 2.0 fold change. A total of 22 
genes were distinctly regulated, 16 genes were up-regulated and 6 
genes were down-regulated
To investigate gene interaction, we clustered 
the gene probes according to signaling pathway with 
PANTHER database. In this study, at least five pathways 
were distinctly regulated in MMD: Angiogenesis 
(Figure 3), inflammation (Figure 4), integrin (Figure 5), 
WNT (Figure 6), and platelet-derived growth factor 
(PDGF) (Figure 7). SOS1 was shown to involve in 
all pathways, but WNT pathway. AKT2 was shown 
to involve in angiogenesis, inflammation, and PDGF 
pathway. Therefore, suggesting the importance of 
SOS1 and AKT2 in MMD.
Discussion
MMD is a steno-occlusive disease, primarily 
affects for brain vessels, or at least affects predominantly 
in cerebral arteries, and the etiology of this unique 
pathological condition remains elusive [1], [2], [24]. 
Recently, RNF213 was identified as a susceptibility 
gene for MMD. RNF213 is located in chromosome 
17q25.3 and c.14576 G>A SNP increased the risk of 
having MMD, particularly in Asian population [4], [5], 
[6], [25].
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Figure 5: Normalized gene expression of distal MCA from MMD 
patients in integrin pathway with > 2.0 fold change. A total of 13 
genes were distinctly regulated, 6 genes were up-regulated, and 7 
genes were down-regulated
Deletion of RNF213 in zebrafish results in 
abnormal sprouting of intracranial vessels and inter-
segmental arteries [4]. The over-expression of RNF213 
in endothelial cells results in poor tube formation and 
decreased of proliferation rate [26]. However, mice 
with RNF213 mutation failed to recapitulate MMD 
phenotype [16], [17]. The pathology of MMD artery is 
characterized by intimal thickening with fibromuscular 
hyperplasia and media layer thinning, remains 
inexplicable through previous RNF213 studies. Hence, 
another approach is necessary to elucidate MMD 
pathobiology.
Figure 6: Normalized gene expression of distal MCA from MMD 
patients in WNT pathway with > 2.0 fold change. A total of 12 genes 
were distinctly regulated, 8 genes were up-regulated, and 4 genes 
were down-regulated
We previously reported that MMD pathology 
extends to distal MCA [11], [22], thus distal MCA 
may serve as valuable resource for MMD research. 
From our microarray study, we obtained that at least 
five pathways were distinctly regulated in distal MCA 
of patients with MMD: Angiogenesis, inflammation, 
integrin, PDGF, and WNT. From further analysis, AKT2 
and SOS1 (son of sevenless homolog 1) were the 
most distinctly regulated genes compare to controls. 
Both AKT2 and SOS1 are related to RAS pathway 
that involves in multiple cellular processes, including 
proliferation, survival, and migration [27]. The RAS 
pathway is activated through integrin and growth factor 
signaling acts the controlling cellular machinery as a 
response to extracellular signal [27], [28].
Figure 7: Normalized gene expression of distal MCA from MMD 
patients in PDGF pathway with > 2.0 fold change. A total of 11 genes 
were distinctly regulated, 8 genes were up-regulated, and 3 genes 
were down-regulated
AKT2 is a member of the protein kinase B 
family and acts as a downstream of RAS pathway, 
has been implicated in several cancer [28]. SOS1 is 
a member of guanosine nucleotide exchange factors 
that increases nucleotide exchange rate of GDP for 
GTP, resulting in RAS activation. Clinically related 
syndrome to SOS1 mutation is Noonan syndrome, a 
member of RASopathies [29]. Noonan syndrome is 
a congenital malformation characterized by variable 
congenital heart defects, short stature, skeletal 
malformations, and distinct facial anomalies [30]. 
In line with our results, moyamoya vasculopathy 
has been reported in patients with Noonan like-
disorders [31], [32], [33], [34], [35], [36]. Moyamoya 
vasculopathy is also likely to occur in patients 
with other forms of RASopathies. Other forms of 
RASopathies: Cardiofaciocutaneous syndrome and 
Von Recklinghausen disease also reported to have a 
higher risk of having moyamoya vasculopathy [37], [38].
Nevertheless, our study has a major limitation 
due to the rarity of the specimens, we could not confirm 
the relevant gene expression on tissue samples. In this 
study, we also obtained a low RNA integrity number, 
suggesting some RNA has been degraded before 
extraction. RNA is susceptible for hydrolysis and rapidly 
degenerates, many manipulations and long duration 
for tissue harvesting, and probably the surgical field 
and tools were not RNAse free, all those factors may 
contribute to low RNA integrity number. We recommend 
for harvesting larger specimens and utilize RNAse free 
A - Basic Sciences Genetics
960 https://www.id-press.eu/mjms/index
surgical tools to minimize enzymatic degradation of 
RNA.
Nevertheless, this investigation is useful as 
a biomolecular screening of abnormal pathways with 
the current available method. In line with our previous 
study, the distal MCA of patients with MMD involves 
in MMD pathology and has a distinct molecular 
expression in comparison to control distal MCA. In this 
study, RAS activation was observed in the distal MCA 
of patients with MMD, presumably contributes to intimal 
proliferation and stenosis of ICA, and thus plays a role 
in MMD pathology. Further investigation is needed to 
confirm the role of RAS pathway in MMD.
Conclusions
Through microarray analysis, we obtained that 
gene expression of distal MCA of patients with MMD 
was distinctly regulated in comparison with control. At 
least 5 pathways were altered in MMD: Angiogenesis, 
inflammation, integrin, PDGF, and WNT. Furthermore, 
SOS1 and AKT2 were the most altered genes in 
those aforementioned pathways. Nevertheless, 
our understanding about MMD pathobiology is still 
immature, further study is necessary.
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